More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.

Also, there were no significant differences between patients with either 2-5% or 5-20% CPCs and those with >= 20% CPCs in PFS and OS ( I P i > 0.05). Compared to patients with < 2% CPCs, median PFS and OS of patients with 2-20% CPCs were 11.2 months (vs 18.8 months, I P i = 0.0001; Fig. [Extracted from the article]